The biggest differences between the development of a biosimilar and a generic medicine lie primarily in the preclinical and clinical stages.
Particle performance in a DPI can be optimized by fine-tuning the formulation and manufacturing process parameters.
Having intelligent analytical tools can advance the detection of unknown impurities, which is important for ensuring small-molecule ingredient purity.
Advancing the use of AI to understand the whole of a disease can reveal drug development insights that lead to drug discovery breakthroughs.
This article provides an overview of solutions to address key challenges facing vaccine developers or CDMOs wishing to build their own commercial-scale mRNA production facilities.
This article presents the results of a survey conducted to gain insight on the impact of the COVID-19 pandemic on biomanufacturing operations.
Utilizing integrated active radio frequency identification (RFID) and real-time asset management systems can yield commercial and compliance benefits.
Change of lot or extension of reference standard shelf-life is considered low risk and should be downgraded from prior-approval to being managed in the Pharmaceutical Quality System (PQS) only based on a science and risk-based approach.
Parenteral drugs are becoming increasingly complex, creating new challenges and opportunities. This paper explores potential innovations across the entire value chain.
Particle characteristics can affect pharmaceutical formulations and products in a number of ways, and a variety of techniques are available that enable particle monitoring and characterisation.
Maintaining a quality culture across the diverse functions in a bio/pharmaceutical company is difficult. Representatives of the Quality Coordinating Committee of IQ Consortium report on collaborative efforts to address data integrity and the modernization of FDA’s good laboratory practice regulations.
Research suggests that intranasal nanosuspensions offer a promising way to formulate and deliver drugs that are poorly soluble in water to patients with chronic conditions.
The application of the first piston syringes to treat medical complications was described in Roman times during the 1st century, and forms of intravenous injection and infusion began as early as 1670.
A data-driven strategy can assess the quality of legacy drugs developed before 2011 process-validation requirements were established.
In this paper, the authors lay out some commonly accepted HCP analytical methods, the challenges of HCP assay, and provide recommendations on what can easily be accomplished in-house and when it may be better to outsource.
The author reviews Warning Letters issued between 2000 and mid-2010 for aseptic processing and non-sterile processing, and determines how many observations were made for each section of the GMPs.
Researchers demonstrated a new cell lysis method using a novel solution to improve viral vector production.
An Overview with Aubrey Hogan Verista’s Head of Regulatory Compliance and Product Lifecycle Management
Shared audits of suppliers offer several advantages, but networking to conduct such an audit can be challenging.
AFI representatives of the process validation working group explore and define key elements for an enhanced approach to process validation for sterile liquid and freeze-dried forms.
Many consumers trust that a Certificate of Analysis (COA) guarantees product safety, but without strict regulatory oversight, that’s not always the case. This white paper provides insights into what consumers and businesses should look for in a truly safe, high-quality, and consistent product.
Interoperability by 2023 depends on data standardization and systems compatibility between trading partners.
Show blasts off this month in Philadelphia with more suppliers, new trends, and real-world solutions.
Research suggests that intranasal nanosuspensions offer a promising way to formulate and deliver drugs that are poorly soluble in water to patients with chronic conditions.
Integrating digital technologies into lab environments can ease workflow and enhance data capture for researchers.
Assessing biosafety using NGS-based tests requires a continuum of skills in molecular biology, biocomputing, virology, and quality systems.
Continued process verification for a cleaning validation program begins once the validation study is complete.
The complexity of the RNA production process creates challenges.
Many biologic drug manufacturers encounter similiar challenges; precompetitive collaboration can help resolve these issues. Representatives of the IQ Consortium’s Biologics CMC Leadership Group describe efforts to address the safe handling of biologic drugs in closed-system transfer devices in healthcare settings and the need for phase-appropriate specifications.
Case studies on the manufacture of a bluk powder and the development of a tablet show the application of QbD principles.